Prasugrel, the upcoming rival to $6 billion drug Plavix, gets a write-up. This is a crucial new drug for co-promote partners Daiichi-Sankyo and Eli Lilly.
Good Samaritan drug rep loses leg, gains lots of supporters.
The ferment continues in the diabetes marketplace. JAMA article further muddies the waters for GSK‘s Avandia, while putting a positive spin on Takeda‘s rapidly ascending rival treatment Actos. Meanwhile, Merck reports encouragement for the Januvia/Janumet family.
King’s Altace reign may soon end with generic competition, while patents on Skelaxin are also under pressure.
Cephalon experiences more pain with Fentora, a painkiller tied to (off-label) deaths.
Propecia, the hair growth drug, and its encouraging uses for prostate cancer.
JUST IN: Lilly’s Evista approved for breast cancer.
And, I’m with the WSJ Health blog on this one. Which drug-coated stent is better? Are they better than bare-metal stents? Does anybody really know what time it is? Sheeeesh.
Leave a Reply